Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

nonvalvular atrial fibrillation
ACC.24: PIONEER AF-PCI Clinical Trial Finds XARELTO (rivaroxaban) Reduces Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
04/09/2024

Johnson & Johnson News

Johnson & Johnson News
A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of...
A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of...
A new analysis of data from the...
04/09/2024
Cath Lab Digest
aorto-iliac occlusive disease
Getinge iCast Covered Stent System Considered Medically Necessary for Treatment of Iliac Arterial Occlusive Disease
04/09/2024

Getinge News

Getinge News
Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents. Aetna issued a revised CPB stating that the iCast covered stent...
Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents. Aetna issued a revised CPB stating that the iCast covered stent...
Getinge announced Aetna, a...
04/09/2024
Cath Lab Digest
Endovascular Imaging
ACC.24: IVUS-DCB - Intravascular Ultrasound Outperforms Angiography for PAD Treatment
04/08/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“IVUS is more accurate than angiography in measuring vessel dimensions. It facilitates achieving sufficient vessel lumen diameters and aids in evaluating the response of the target lesion to treatment,” said Young-Guk Ko, MD, the study’s lead...
“IVUS is more accurate than angiography in measuring vessel dimensions. It facilitates achieving sufficient vessel lumen diameters and aids in evaluating the response of the target lesion to treatment,” said Young-Guk Ko, MD, the study’s lead...
“IVUS is more accurate than...
04/08/2024
Cath Lab Digest

Advertisement

Heart Valve Disease Awareness
New Survey Uncovers Lack of Awareness Around Heart Valve Disease and Risk Factors Among Women
04/08/2024

Medtronic News

Medtronic News
"When compared to male patients, female patients often present with more advanced symptoms of heart valve disease, highlighting the importance of uncovering how we can best educate women on early warning signs and treatment options sooner,"...
"When compared to male patients, female patients often present with more advanced symptoms of heart valve disease, highlighting the importance of uncovering how we can best educate women on early warning signs and treatment options sooner,"...
"When compared to male patients,...
04/08/2024
Cath Lab Digest
Hypertension
ACC.24: SPYRAL HTN Clinical Program Data Show Durability of Medtronic Renal Denervation System
04/08/2024

Medtronic News

Medtronic News
Long-term durability data showed clinically meaningful, safe and sustained blood pressure (BP) reductions (-23.2 mmHg in office systolic BP and -14.0 mmHg reductions in 24-hour ambulatory BP) in patients with uncontrolled hypertension.
Long-term durability data showed clinically meaningful, safe and sustained blood pressure (BP) reductions (-23.2 mmHg in office systolic BP and -14.0 mmHg reductions in 24-hour ambulatory BP) in patients with uncontrolled hypertension.
Long-term durability data...
04/08/2024
Cath Lab Digest
CVD Awareness
ACC.24: HUDDLE Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
04/08/2024

Edwards Lifesciences News

Edwards Lifesciences News
Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
Results of the HUDDLE study...
04/08/2024
Cath Lab Digest

Advertisement

Mechanical Circulatory Support
ACC.24: DanGer Shock Randomized Controlled Trial Confirms Impella CP Improves Survival in Heart Attack with Cardiogenic Shock
04/08/2024

Abiomed News

Abiomed News
A late-breaking clinical trial confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).
A late-breaking clinical trial confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).
A late-breaking clinical trial...
04/08/2024
Cath Lab Digest
Cholesterol Therapy
ACC.24: New V-INITIATE Trial Data Show Early Addition of Twice-Yearly* Leqvio (inclisiran) Following Maximally Tolerated Statin Therapy Significantly Reduces LDL-C in ASCVD
04/08/2024

Novartis News

Novartis News
New data demonstrate the early addition of twice-yearly* Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol...
New data demonstrate the early addition of twice-yearly* Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol...
New data demonstrate the early...
04/08/2024
Cath Lab Digest
Hypertension
ACC.24: KARDIA-2 Phase 2 Study Shows Positive Results for Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
04/07/2024

Alnylam Pharmaceuticals, Inc., News

Alnylam Pharmaceuticals, Inc., News ...
The KARDIA-2 study achieved its primary endpoint demonstrating clinically and statistically significant additive, placebo-adjusted reductions of up to 12.1 mmHg in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood...
The KARDIA-2 study achieved its primary endpoint demonstrating clinically and statistically significant additive, placebo-adjusted reductions of up to 12.1 mmHg in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood...
The KARDIA-2 study achieved its...
04/07/2024
Cath Lab Digest

Advertisement

Aspirin & Ticagrelor
ACC.24: ULTIMATE-DAPT - Stopping Aspirin One Month After Coronary Stenting Procedures Significantly Reduces Bleeding Complications in Heart Attack Patients
04/07/2024

Mount Sinai News

Mount Sinai News
Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients...
Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients...
Withdrawing aspirin one month...
04/07/2024
Cath Lab Digest

Advertisement

Advertisement

Subscriber

Cath Lab Digest Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use